key: cord-0981811-b07al6tj
authors: Haghighi, Mahdi Montazer; Kakhki, Erfan Ghani; Sato, Christine; Ghani, Mahdi; Rogaeva, Ekaterina
title: The Intersection between COVID-19, the Gene Family of ACE2 and Alzheimer’s Disease
date: 2020-11-22
journal: Neurosci Insights
DOI: 10.1177/2633105520975743
sha: 8c87cc8b16a49b4b36cecf592e2e5c1fbecea797
doc_id: 981811
cord_uid: b07al6tj

We reviewed factors that might influence COVID-19 outcomes (eg, neurological symptoms), including the link to Alzheimer’s disease. Since the virus triggers COVID-19 infection through binding to ACE2, we focused on the ACE2 gene family, including ACE. Both ACE2 and ACE are involved in the renin–angiotensin system (RAS). In general, ACE causes inflammation and vasoconstriction, while ACE2 leads to anti-inflammation activity and vasodilation. The disturbed balance between these counter-regulatory pathways could influence susceptibility to COVID-19. Notably, dysregulation of the RAS-equilibrium contributes to Alzheimer’s disease. Differences in the incidence and symptoms of COVID-19 in diverse populations could be attributed to variability in the human genome. For example, ACE and ACE2 variations could modify the outcome of COVID-19 in different populations. It would be important to conduct genome-wide studies to detect variants influencing COVID-19 presentation, with a special focus on variants affecting immune-related pathways and expression of RAS-related genes.

The global outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing coronavirus disease 2019 (COVID- 19) has posed a risk to the global economy and public health. Severe presentations of COVID-19 are most frequent among individuals above age 65 with the most likely cause of death due to respiratory failure. 1 In some patients, even clinically mild respiratory symptoms could be inconsistent with the high severity of imaging findings. 1 SARS-CoV-2 is a new strain of SARS-CoV, which was responsible for the outbreak of severe acute respiratory syndrome (SARS) in 2002-2003. 2, 3 Both strains use angiotensin-converting enzyme 2 (ACE2) as the receptor to enter host-cells, 4 with virus entry enhanced by cellular transmembrane serine protease 2 (TMPRSS2). Infection begins with the linking of the viral spike protein (S-protein) to ACE2 after the S-protein has been primed by TMPRSS2. 5 Hence, cells expressing both TMPRSS2 and ACE2 are targets for anchoring the virus.

Efficiency of ACE2 usage is a key determinant of virus transmissibility. [6] [7] [8] According to the Genevestigator database (https://www.genevestigator.com), the highest expression of ACE2 is seen in small intestine, germ cells, kidney, and heart ( Figure 1(a) ), which also have high levels of TMPRSS2 expression (Figure 1(b) ). Yet, diarrhea has been reported in only 10% of COVID-19 patients. 9 Notably, lung tissue has only a medium level of ACE2 expression, which suggests that interacting mechanisms (eg, the neuroinvasive potential of SARS-CoV-2) might be responsible for the respiratory failure of COVID-19 patients. 10 About 30% of hospitalised COVID-19 patients develop neurological symptoms, including ataxia, agitation, delirium, headache, cerebrovascular disease, epilepsy, loss of taste and smell, as well as diffuse corticospinal tract signs (with enhanced tendon reflexes, ankle clonus, and bilateral extensor plantar reflexes). 11,12 ACE2 expression is low/medium in the nervous system indicating that brain dissemination may occur via the circulatory system or nasal cavity through the olfactory nerve, which could explain alterations in sense of smell. 13, 14 The virus could also infect the brain through a disrupted blood-brain barrier that is often compromised in the aging brain and neurodegenerative diseases, 15 especially in Alzheimer's disease (AD).

AD accounts for up to 75% of all dementia cases with typical onset after age 65. 16 Brain pathology of AD is characterized by neuronal loss, neuroinflammation, neuronal inclusions of hyperphosphorylated tau protein, as well as parenchymal and vascular Aβ-amyloid deposits. 16 Alterations in cerebral blood vessels have a profound impact on cognitive function. 17 Some COVID-19 patients might develop cognitive decline after overcoming the primary infection, 18 which in part could be explained by the virus-related exacerbation of the underlying brain pathology in elderly individuals. 15 In an attempt to delineate the factors that may influence COVID-19 outcome (eg, neurological symptoms), the current review is focused on the ACE2 gene family and genetic

The Intersection between COVID-19, the Gene Family of ACE2 and Alzheimer's Disease 

ACE2 is mapped to the Xp22.2 locus and encodes the 805 amino acid metallopeptidase that shows mono carboxypeptidase activity with a preference for C-terminal hydrophobic or basic residues. [19] [20] [21] ACE2 is an integral protein in cell membranes with 4 domains: N-terminal signal peptide sequence (residues 1-18), transmembrane domain (residues 740-763), C-terminal domain (residues 614-805), and catalytic extracellular domain (residues 147-555), which includes a zinc binding site (His-Glu-Met-Gly-His; residues 374-378). 2, 19, 20, 22 SARS-CoV-2 or SARS-CoV infection begins with the linking of the viral S-protein with Ser19-Asp615 of ACE2. 23 Site-directed mutagenesis of ACE2 revealed that the charged amino acids (residues 22-57) are the most important for binding of the S-protein. 2, 24 Changing several ACE2 residues (Lys31, Tyr41, 82Met-84Pro, Asp355, and Arg357) interferes with the binding of S-protein to host-cells. Strikingly, the Lys31Asp substitution almost completely inhibits binding of ACE2 to S-protein; and the critical role of Lys31 was reported for both SARS-CoV 24 and SARS-CoV-2 4 (Figure 2(a) ). Notably, Lys31 is a conserved codon, affected by only 1 rare synonymous variant (rs758278442). Taken together, some ACE2 residues are essential in determining susceptibility to SARS-CoV-2 infection and can be exploited as potential drug targets. 2 A paralogue of ACE2 is angiotensin I converting enzyme (ACE), which is mapped to the 17q23.3 locus and encodes the 1306 amino acid zinc-dependant dipeptidyl carboxypeptidase (Figure 2 (b)-(d)). The highest expression of ACE is seen in the small intestine and lung (Figure 1(c) ). ACE and ACE2 were derived from a common ancestor (Figure 2(c)); 2,19,25 and have 60% similarity in their genomic structures, 3 as well as 40% identity based on the outcome of a nucleotide BLAST. ACE is likely the result of an internal gene duplication event, because it has 2 homologous domains with 60% sequence identity (encoded by exons 4-11 and 17-24). 25 Despite ACE harboring 2 regions homologous to the virus-binding site of ACE2, no affinity between the virus and ACE have been reported. This could be explained by the low amino acid homology (only 32% and 24%) between ACE2 residues 20-79 and each homologous domain of ACE (residues 41-100 and 644-703, respectively). 21, 25 Of note, the positively charged critical Lys31 in ACE2 is aligned with the partially charged Ser52 and negatively charged Glu655 in each homologous domain of ACE ( Figure 2 (d)).

Another gene homologous to ACE2 is CLTRN ( Figure  2 (c)), which is mapped to the Xp22.2 locus (26 Kb from ACE2) and almost exclusively expressed in kidney. 26-28 CLTRN encodes a type 1 transmembrane protein (collectrin) that is essential for trafficking amino acid transporters to the apical brush border of proximal tubules in the kidney. Disruption of CLTRN in mice led to a severe defect in renal amino acid uptake. 29 Up-regulated expression of CLTRN in hypertrophic kidneys after renal ablation indicates the role of CLTRN in the process of progressive renal failure. 27 The results of a nucleotide BLAST show 50% identity between ACE2 and CLTRN. However, CLTRN lacks the catalytic domain required for virus binding. 19, 26, 27 

ACE and ACE2 work together in the renin-angiotensin system (RAS) controlling blood pressure and the homeostasis of electrolytes. ACE leads to degradation of bradykinin (vasodilator) 19, 27 ; and also alters angiotensin I circulating in plasma to generate the vasoconstrictor angiotensin II, which binds to angiotensin II type 1 receptor to enhance systemic blood pressure. 19, 27 Hence, blocking ACE is effectively used to control hypertension. In contrast, a negative regulator of RAS is ACE2, which converts angiotensin II into a vasodilator (angiotensin 1-7) 28 and also turns angiotensin I into angiotensin 1-9. 19 Furthermore, ACE and ACE2 are involved in inflammatory processes (eg, in lung injury, pulmonary hypertension, and sepsis). 30 In general, ACE causes inflammation and vasoconstriction, 31, 32 while ACE2 leads to anti-inflammation activity and vasodilation. 33 The disturbed balance of the counter-regulatory ACE and ACE2 pathways could influence susceptibility to COVID-19. Indeed, individuals with hypertension, diabetes or heart disease (known AD risk factors 34 ), who are under treatment with ACE inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs), are reported to be more vulnerable to COVID-19. 35, 36 These treatments could suppress ACE expression and as a result induce upregulation of ACE2 on the cell surface, potentially leading to increased viral entry. 6, 26, 35, 37 However, some studies do not support withdrawal of ACEI/ARB treatment in COVID-19 patients. For instance, COVID-19 patients receiving ACEIs or ARBs had a lower rate of disease severity. 38 Furthermore, a recent Danish study reported that ACEI/ARB therapy is not Neuroscience Insights associated with increased susceptibility to SARS-CoV-2 infection or COVID-19 severity. 39

Clinical findings indicate the involvement of the brain in COVID-19, 11 and a diagnosis of dementia represents an important risk factor for mortality in COVID-19 patients. 40 Notably, dysregulation of the RAS-equilibrium in brain (eg, by increased ACE and angiotensin II levels) contributes to the aetiology of several neurodegenerative diseases, including AD. [41] [42] [43] Brain vasculature has a close structural and functional relationship with brain tissue, and their cellular elements form a functional domain (neurovascular unit). 17 Both cortical and subcortical structures are involved in a complex communication between the nervous and cardiovascular system. 15 One of the mechanisms linked to the neurovascular axis is related to brain-derived neurotropic factor (BDNF), which plays a role in both neurogenesis and vasculogenesis. Decreased BDNF expression with age could increase susceptibility to cardiac injury and exacerbate cognitive decline. 15 Notably, the common BDNF variation (Val66Met; rs6265) results in a 30% reduction in BDNF secretion and has been linked to a wide range of neurological conditions, including risk of AD. 44 It remains to be determined whether BDNF variation(s) could modify the phenotype of COVID-19 patients.

Activation of the ACE-related pathway in the brain, leads to oxidative stress, neuroinflammation and decreased cognitive function through enhanced levels of angiotensin II. In AD brain, ACE2 activity was reported to be reduced in association with increased Aβ and tau pathology; and the ACE/ACE2 ratio was higher compared to controls. 45 Investigation of the frontal and temporal cortices revealed that ACE2 is localized predominantly within endothelial cells and smooth muscle cells of cerebral arteries. 45 Intriguingly, a study on a small autopsy cohort reported a 5-fold upregulated expression of ACE2 in AD brain (n = 13) compared to controls (n = 5), which could lead to higher viral load in AD brain. 46 Notably, ACEI/ARB therapy is commonly administered to individuals with neurodegenerative diseases (eg, AD) in order to improve cognition, 47, 48 which leads to the downregulation of ACE but upregulation of ACE2. Such therapy could elevate the risk of severe COVID-19 infection. [48] [49] [50] Recently, SARS-CoV-2 proteins were expressed in human cells, which identified 332 high-confidence protein-protein interactions between human and virus proteins. 51 About 40% of human virus-interacting proteins were associated with endomembrane compartments or vesicle trafficking pathways, including 2 AD-related proteins (ADAM9 and ADAMTS1) involved in vesicle trafficking with viral ORF8 protein implicated in protein quality control in the endoplasmic reticulum. ADAM9 is one of the α-secretases cleaving APP in the middle of the Aβ-domain, 52 which is a protective pathway in AD. ADAMTS1 is involved in various inflammatory processes, 53 and upregulated in the brains of patients with Down syndrome, Pick's disease, and AD. 54, 55 Importantly, ADAMTS1 was recently suggested as a risk locus for AD by a large genetic study. 56 

Differences in the incidence and symptoms of COVID-19 in diverse populations 57, 58 could be attributed to variability in the human genome. Genetic variations in the 2 major components of RAS (ACE and ACE2) may in part explain why SARS-CoV-2 infection shows different morbidity and mortality among different populations. Variations in ACE2 and ACE were linked to hypertension in Chinese, [59] [60] [61] [62] Indian, 63 and Brazilian 64 cohorts. Furthermore, a gene-candidate approach 65 and genome-wide association studies in European datasets 56 demonstrated that ACE is genetically involved in AD. In addition, ACE variants were associated with several other traits, based on the NHGRI-EBI Catalog of published genome-wide association studies (Table 1) .

Recent investigation of an ACE intronic 289 bp insertion/ deletion (rs4646994) in 33 countries of Europe, North Africa and Middle East revealed that the prevalence of COVID-19 is negatively correlated with the frequency of the deletionallele. Through the RAS, the ACE deletion-allele is associated with reduced ACE2 expression, suggesting a protective effect against COVID-19. 57 The same ACE deletion-allele was more frequent among 66-70 year old AD cases versus controls. 65 Numerous other genetic variants could alter ACE and ACE2 gene expression, according to the genotype-tissue expression data at GTEx portal (https://www.gtexportal. org/). 66 Such variations could change the balance between the 2 RAS pathways and modify the clinical presentation of COVID-19. For instance, low expression levels of cardiac and renal ACE2 were associated with high blood pressure and diabetes, respectively; 67 and altered gene expression of several components of the RAS were linked to AD and other neurodegenerative diseases. 68 Intriguingly, a UK study reported a link of COVID-19 with APOE. 69 The APOE ε4-allele is a major risk factor for AD, whereas the ε2-allele protects against AD. 70 Risk of severe COVID-19 infection was reported to be increased in ε4/ε4carriers based on the observation that ε4/ε4-carriers were twice as likely to test positive for COVID-19 compared to ε3/ε3carriers. 69 This association was independent of pre-existing dementia, cardiovascular disease, and diabetes. However, the definition of severe COVID-19 was based on a general consideration that during the peak outbreak in the UK, COVID-19 testing was mainly restricted to patients with clinical signs of infection, and therefore a positive test would be a marker of severe infection. Moreover, the cohort size was modest (622 COVID-19 patients, including only 37 ε4/ε4-carriers); and validation in an independent dataset has not been conducted.

Furthermore, it would be important to assess the potential protective effect of the ε2-allele in COVID-19 patients.

Notably, the APOE locus was not detected by a genomewide approach using a cohort of Italian and Spanish COVID-19 patients with respiratory failure. 71 However, this study identified 2 risk loci. The association signal at the 3p21.31 locus implicated a cluster of 6 genes, including SLC6A20, which encodes a protein that functionally interacts with ACE2, while the signal at 9q34.2 coincides with the locus encoding the ABO blood groups. A higher risk of severe COVID-19 was observed among individuals from blood group A, while blood group O was linked to a protective effect, which agrees with non-genetic studies implicating the ABO blood groups in COVID-19 susceptibility. Compared with individuals with other blood types, those with type A had a 45% higher risk of developing severe COVID-19, while people with type O had a 35% lower risk. Importantly, blood type O is also associated with larger volumes of gray matter in the cerebellum and temporal-mediotemporal/limbic regions, suggesting its protective role against AD. 72, 73 It is possible that the protective effect of blood type O is linked to a reduced risk of thrombotic adverse events compared to individuals with other blood types.

Variability in the virus genome itself could also contribute to COVID-19 severity. 74 For instance, the 11083-G variant in the genome of SARS-CoV-2 is more commonly found in symptomatic patients, while the 11083-T variant is more frequent in asymptomatic patients. 75 In addition, a 382-bps deletion in the viral genome was associated with COVID-19 infection in the Middle East. 76 Furthermore, some individuals may have primary immunodeficiencies predisposing them to severe COVID-19. For instance, a whole-exome study of 4 young males with severe COVID-19 detected loss-of-function variants in TLR7 leading to immunological defects in interferon production. 77 It would be important to assess the contribution of other immune-related genes to COVID-19 severity, including loci suggested by studies of AD and related neurodegenerative diseases, many of which point to immune-related pathways, including human leukocyte antigen (HLA) region at 6p21.32 locus. 56 For instance, there is a need to establish which HLA alleles contribute to protection or risk of COVID-19 and their relevance to risk of AD. Notably, severe COVID-19 outcomes are often associated with a "cytokine storm" of pronounced inflammation, which may be in part associated with a higher baseline of inflammation in elderly individuals (eg, affected by AD). 34

Both genetic and non-genetic factors affecting the ACE2/ ACE pathways must be investigated to find the most effective therapeutic intervention against COVID-19 infection. For instance, COVID-19 outcome could be influenced by factors disturbing the balance of the RAS pathways (eg, altering expression of ACE2 and ACE), which could contribute to neurological complications reported in many hospitalized patients. COVID-19 could also affect the nervous system in the long term. 78 Genetic architecture likely contributes to the diversity in symptoms and incidence of COVID-19 among different ethnic groups. Hence, it would be important to conduct genome-wide studies to detect variants influencing disease presentation in COVID-19 patients from different populations, with a special focus on variants affecting immunerelated pathways (eg, polymorphisms in HLA genes) expression of TMPRSS2, ACE2 and other RAS-related genes, which have a high potential to contribute to the severity of the viral infection.

Acute respiratory failure in COVID-19: is it "typical

Identification of critical determinants on ACE2 for SARS-CoV entry and development of a potent entry inhibitor

Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus

Receptor recognition by the novel coronavirus from wuhan: an analysis based on decade-long structural studies of SARS coronavirus

SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor

Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis

High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Diarrhea during COVID-19 infection: pathogenesis, epidemiology, prevention, and management

The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients

Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China

Neurologic features in severe SARS-CoV-2 Infection

Olfactory dysfunction in COVID-19

Nervous system involvement after infection with COVID-19 and other coronaviruses

Does SARS-CoV-2 infection cause chronic neurological complications?

Late-onset vs nonmendelian earlyonset alzheimer disease: a distinction without a difference?

The pathobiology of vascular dementia

Immediate and longterm consequences of COVID-19 infections for the development of neurological disease

A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9

A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase

Ace revisited: a new target for structure-based drug design

Searching therapeutic strategy of new coronavirus pneumonia from angiotensin-converting enzyme 2: the target of COVID-19 and SARS-CoV

Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor

Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2

Structure of the angiotensin I-converting enzyme gene. Two alternate promoters correspond to evolutionary steps of a duplicated gene

Collectrin, a homologue of ACE2, its transcriptional control and functional perspectives

Collectrin, a collecting duct-specific transmembrane glycoprotein, is a novel homolog of ACE2 and is developmentally regulated in embryonic kidneys

Chapter 25 -ACE2 cell biology, regulation, and physiological functions

Essential role for collectrin in renal amino acid transport

ACE and ACE2 in inflammation: a tale of two enzymes

Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases

Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system

ACE2, angiotensin-(1-7) and Mas receptor axis in inflammation and fibrosis

Potential novel role of COVID-19 in Alzheimer's disease and preventative mitigation strategies

Clinical characteristics of coronavirus disease 2019 in China

Editorial: COVID-19 spiraling of frailty in older Italian patients

Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection

Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension

Association of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use with COVID-19 diagnosis and mortality

Clinical presentation of COVID19 in dementia patients

Reduced angiotensin II levels in the cerebrospinal fluid of patients with amyotrophic lateral sclerosis

A role for the brain RAS in Alzheimer's and Parkinson's diseases

Brain renin-angiotensin system and microglial polarization: implications for aging and neurodegeneration

Does BDNF Val66Met contribute to preclinical Alzheimer's disease?

Angiotensin-converting enzyme 2 is reduced in Alzheimer's disease in association with increasing amyloid-beta and tau pathology

Angiotensin-converting enzyme 2 (ACE2) is upregulated in Alzheimer's disease brain

Evidence to consider Angiotensin II receptor blockers for the treatment of early Alzheimer's disease

Associations of antihypertensive treatments with Alzheimer's disease, vascular dementia, and other dementias

SARS-CoV2: should inhibitors of the renin-angiotensin system be withdrawn in patients with COVID-19?

World Health Organization. COVID-19 and the use of angiotensin-converting enzyme inhibitors and receptor blockers. World Health Organization

A SARS-CoV-2 protein interaction map reveals targets for drug repurposing

Putative function of ADAM9, ADAM10, and ADAM17 as APP alpha-secretase

METH-1, a human ortholog of ADAMTS-1, and METH-2 are members of a new family of proteins with angio-inhibitory activity

Proteases upregulation in sporadic Alzheimer's disease brain

Metalloproteinase ADAMTS-1 but not ADAMTS-5 is manifold overexpressed in neurodegenerative disorders as Down syndrome, Alzheimer's and Pick's disease

Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Abeta, tau, immunity and lipid processing

COVID-19 infections are also affected by human ACE1 D/I polymorphism

Comparative genetic analysis of the novel coronavirus (2019-nCoV/SARS-CoV-2) receptor ACE2 in different populations

Association of ACE, ACE2 and UTS2 polymorphisms with essential hypertension in Han and Dongxiang populations from north-western China

Correlation of angiotensin-converting enzyme 2 gene polymorphisms with stage 2 hypertension in Han Chinese

Polymorphisms of ACE2 gene are associated with essential hypertension and antihypertensive effects of Captopril in women

ACE2 gene polymorphism and essential hypertension: an updated meta-analysis involving 11,051 subjects

Association of angiotensin-converting enzyme and angiotensin-converting enzyme-2 gene polymorphisms with essential hypertension in the population of Odisha

The combination of ACE I/D and ACE2 G8790A polymorphisms revels susceptibility to hypertension: a genetic association study in Brazilian patients

Association between angiotensin-converting enzyme and Alzheimer disease

Genetic effects on gene expression across human tissues

Decreased glomerular and tubular expression of ACE2 in patients with type 2 diabetes and kidney disease

Renin-angiotensin system gene expression and neurodegenerative diseases

APOE e4 genotype predicts severe COVID-19 in the UK Biobank community cohort

Genetic complexity of early-onset Alzheimer's disease

Genomewide association study of severe Covid-19 with respiratory failure

ABO blood group and neurodegenerative disorders: more than a casual association

O' blood type is associated with larger grey-matter volumes in the cerebellum

The role of host genetics in the immune response to SARS-CoV-2 and COVID-19 susceptibility and severity

SARS-CoV-2 genetic variations associated with COVID-19 severity

SARS-CoV-2 genomic surveillance in Taiwan revealed novel ORF8-deletion mutant and clade possibly associated with infections in Middle East

Presence of genetic variants among young men with severe Covid-19

Effects of COVID-19 on the nervous system

All authors participated in the writing of the manuscript.

Ekaterina Rogaeva https://orcid.org/0000-0002-2852-0329